Showing results (61-70 of 85) with videos related to
Sort By:
Pageof 9
European Journal of Cancer (Oxford, England : 1990)|September 7, 2016
Health-related quality of life in the randomised KEYNOTE-002 study of pembrolizumab versus chemotherapy in patients with ipilimumab-refractory melanomaDirk Schadendorf, Reinhard Dummer, Axel Hauschild, et al.The Journal of Clinical Investigation|May 10, 2016
Immune activation and response to pembrolizumab in POLE-mutant endometrial cancerJanice M Mehnert, Anshuman Panda, Hua Zhong, et al.Nature Cancer|September 3, 2021
Autophagy promotes growth of tumors with high mutational burden by inhibiting a T-cell immune responseLaura Poillet-Perez, Daniel W Sharp, Yang Yang, et al.Cancer Gene Therapy|June 22, 2019
Phase I neoadjuvant study of intravesical recombinant fowlpox-GM-CSF (rF-GM-CSF) or fowlpox-TRICOM (rF-TRICOM) in patients with bladder carcinomaDaniella E Portal, Robert E Weiss, Malgorzata Wojtowicz, et al.Cancer|April 23, 2020
Pembrolizumab for the treatment of programmed death-ligand 1-positive advanced carcinoid or pancreatic neuroendocrine tumors: Results from the KEYNOTE-028 studyJanice M Mehnert, Emily Bergsland, Bert H O'Neil, et al.JAMA Oncology|March 25, 2021
Chronic Immune-Related Adverse Events Following Adjuvant Anti-PD-1 Therapy for High-risk Resected MelanomaJ Randall Patrinely, Rebecca Johnson, Aleigha R Lawless, et al.Oncoimmunology|February 25, 2021
A multicenter characterization of hepatitis associated with immune checkpoint inhibitorsJ Randall Patrinely, Ben McGuigan, Sunandana Chandra, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 1, 2026
Intismeran Autogene Plus Pembrolizumab Versus Pembrolizumab Alone in High-Risk Resected Melanoma: 5-Year Update of the Randomized Phase 2b KEYNOTE-942 StudyAdnan Khattak, Matteo S Carlino, Tarek Meniawy, et al.Nature Medicine|October 6, 2020
Continuous versus intermittent BRAF and MEK inhibition in patients with BRAF-mutated melanoma: a randomized phase 2 trialAlain P Algazi, Megan Othus, Adil I Daud, et al.Journal of the National Cancer Institute|November 21, 2017
Immune Activation and Benefit From Avelumab in EBV-Positive Gastric CancerAnshuman Panda, Janice M Mehnert, Kim M Hirshfield, et al.Pageof 9